Acasti Pharma Inc (NASDAQ:ACST) has received government grants of CAD 750,000. The company expects to report upbeat results of TRILOGY 1 in December 2019. It will also release the results of TRILOGY 2 in January 2020. Acasti completed 95% of the data cleanup for TRILOGY 1. The company will present the results of important exploratory and secondary endpoints of interest that include HbA1c, HDL-C, VLDL, and non-HDL-C at various scientific conferences beginning with Q1 2020.
Chief Executive Officer and President of Acasti, Jan D’Alvise, said the company is on track to publish topline results of TRILOGY 2 and TRILOGY 1 in January 2020 and December 2019. The team at Acasti eagerly awaits the outcome of TRILOGY 2 and TRILOGY 1 trials for various reasons that include the demonstration of the reduction of triglycerides in 675 patients and the positive effect of the CaPre on lipid makers (HDL-C, LDL-C, VLDL, and HbA1c) in patients who have diabetes.
Enrolls patients with higher triglyceride levels
Acasti has enrolled patients with higher triglyceride levels of over 500 mg/dL in phase 3 clinical trial, whereas phase 2 it enrolled patients with triglyceride levels lower than 500 mg/dL.
The company reported a positive response in phase 2 studies on administering daily 1, 2, and 4 grams for eight to twelve weeks. It augurs well for the phase 3 clinical trial. In this trial, the patients (in CaPre) will be administered with 4 grams daily for six months Acasti expects that CaPre would become the best in class omega-3 because of the greater bioavailability and Trifecta effect in patients, who are on a restricted low-fat diet recommended by the physician. All the positive benefits are possible because of the unique blend of DHA, EPA, and phospholipids. As of today, CaPre has not reported any safety concerns or negative side effects.
Signs accord with Aker BioMarine
As part of the commercialization efforts, Acastica entered a pact with Aker BioMarine. According to the terms of the supply pact, Aker will supply RKO (raw krill oil) for two years to Acasti. No price escalation is allowed for two years under this supply accord.
According to the statistical findings, Omega-3 phospholipid (CaPre) expects to promote the secretion of insulin. It exhibited considerable enhancement in plasma levels of PDX and 17S-HDHA when compared to icosapent ethyl and metformin. CaPre is used to treat severe HTG (hypertriglyceridermia). It also improves insulin production and beneficial for diabetes patients.